SCM
Sarissa Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $38.1M | Sell |
303,151
-5,965
| -2% | -$750K | 24.68% | 2 |
|
|
2025
Q1 | $34.2M | Hold |
309,116
| – | – | 22.1% | 2 |
|
|
2024
Q4 | $42.2M | Sell |
309,116
-101,367
| -25% | -$13.8M | 13.07% | 3 |
|
|
2024
Q3 | $47.3M | Hold |
410,483
| – | – | 11.76% | 5 |
|
|
2024
Q2 | $56.5M | Buy |
410,483
+64,057
| +18% | +$8.82M | 9.54% | 6 |
|
|
2024
Q1 | $47.8M | Sell |
346,426
-123,574
| -26% | -$17M | 8.36% | 5 |
|
|
2023
Q4 | $61.9M | Buy |
470,000
+104,000
| +28% | +$13.7M | 9.54% | 5 |
|
|
2023
Q3 | $41.2M | Buy |
366,000
+134,700
| +58% | +$15.2M | 5.55% | 6 |
|
|
2023
Q2 | $21.8M | Buy |
+231,300
| New | +$21.8M | 2.17% | 6 |
|